- Trial phase
- Phase 1
- Time to market
- If the Phase 1 update supports the registrational study planned for H1 2027, a potential FDA approval would likely be several years away, assuming successful pivotal trial execution. The Fast Track designation could accelerate timelines, but the drug is still in Phase 1 development.
- Why 7/10
- The next hard, dated catalyst is the Phase 1 monotherapy data update in metastatic colorectal cancer expected in January 2027 (roughly 2 months away). This is a Phase 1 update, not a pivotal readout or PDUFA, but Varseta-M is the company's lead and primary value-driving asset. The stock trades near cash value, so a positive data update could drive substantial upside, while a negative readout could push shares toward the 52-week low.
The next major catalyst is the Phase 1 monotherapy data update in mCRC expected in January 2027 (roughly 2 months away). Positive data could support the planned registrational study start in H1 2027 and drive significant upside given the stock trades near cash value. Disappointing efficacy or safety signals could delay the pivotal program and pressure the stock toward its 52-week low of $2.11.
Price Chart
Executive Summary
Varseta-M (varsetatug masetecan, CX-2051) is CytomX Therapeutics' lead drug candidate, a masked antibody-drug conjugate (ADC) targeting EpCAM for relapsed/refractory metastatic colorectal cancer. Phase 1 dose expansion data from March 2026 showed 20-32% response rates and median progression-free survival of 6.8-7.1 months in heavily pretreated patients. The FDA granted Fast Track Designation in August 2026. The next catalyst is a Phase 1 monotherapy data update expected in January 2027, which will inform dose selection and the planned registrational study start in H1 2027. The stock trades at $2.19 near its 52-week low, with analyst consensus strongly bullish (13 of 14 Buy/Strong Buy, mean target $12.25) and cash runway into H2 2028 after a $250M March 2026 offering.
How It Works
Varseta-M is a 'masked' antibody-drug conjugate (ADC) -- a precision cancer therapy that combines an antibody targeting EpCAM (a protein found on many cancer cells) with a chemotherapy payload (a topoisomerase-1 inhibitor). The masking technology (CytomX's Probody platform) keeps the drug inactive in healthy tissue; it only becomes active in the tumor environment where certain enzymes (proteases) are abundant. This design aims to reduce side effects while delivering the chemotherapy directly to cancer cells.
Trial Status
Phase 1 dose expansion in mCRC completed with data reported March 2026. A Phase 1 monotherapy data update is expected in January 2027 to support dose selection. A Phase 1 combination study with bevacizumab in 3L+ mCRC is ongoing. The company plans to initiate a registrational study in H1 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 monotherapy data update in mCRC (January 2027)
- Potential registrational study initiation in mCRC (H1 2027)
- Phase 1 combination data with bevacizumab (timing not specified)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CytomX Therapeutics, Inc. 8-K CTMX ·Originating report